Touching Base

Agentic AI, Virtual Cell, LNP Vaccine Boosters, Engineered Organs, and Mergers

Thu, 26 Mar 2026 19:41:46 GMT

This week, agentic AI steps into the limelight buoyed by the momentum from generative AI. And there’s a new virtual cell model in town courtesy of AI-drug developer Xaira Therapeutics. From the frontiers of AI, our discussion turned to feats of engineering in regenerative medicine and lipid nanoparticles. In one study, scientists redesigned LNPs to avoid the liver and accumulate in the lymph nodes. In the other, efforts to develop and implant a lab grown esophagus from donor pigs bear fruit. Finally, Novartis plans to spend up to $3 billion to expand its cancer pipeline with the acquisition of Pikavation Therapeutics. And Merck is acquiring Terns Pharmaceuticals for approximately $6.7 billion also with an eye towards boosting its cancer portfolio.

Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, Uduak Thomas and Alex Philippidis for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

NVIDIA GTC 2026: Agentic AI Inflection Hits Healthcare and Life Sciences

By Fay Lin, PhD, GEN Edge, March 18, 2026

Xaira’s First Virtual Cell Model Is Largest To-Date, Toward Complex Biology

By Fay Lin, PhD, GEN Edge, March 25, 2026

Modified Lipid Nanoparticles Boost mRNA Vaccine Delivery to Lymph Nodes

GEN, March 24, 2026

Engineered Esophagus Rebuilds Missing Organ Segment in Pig Models

GEN, March 20, 2026

Novartis Acquires Pikavation for Up to $3B, Expanding Cancer Pipeline

GEN, March 22, 2026

Merck Bolsters Cancer Pipeline with $6.7B Terns Buyout

By Alex Philippidis, GEN Edge, March 25, 2026

Touching Base Podcast

Hosted by Corinna Singleman, PhD

Behind the Breakthroughs

Hosted by Jonathan D. Grinstein, PhD

Hosted on Acast. See acast.com/privacy for more information.

Bacteria 4D Simulation, Safer Large Gene Insertion, uniQure Roller Coaster

Fri, 13 Mar 2026 01:12:28 GMT

A new study from the J. Craig Venter Institute simulates the complete life cycle of a minimal bacterial cell in 4D space and time at nanoscale resolution. Meanwhile, in gene editing, a new technology has designed DNA donors that evade the immune system, allowing safer large gene insertion that is one step closer to scalable mutation-agnostic therapies. In brain diseases, researchers have found a novel blood-based biomarker that can predict a woman’s risk of developing dementia as many as 25 years before symptoms appear. Our episode rounds out with uniQure’s roller coaster stock, following Vinay Prasad, MD, and his second departure from the FDA.

Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, Uduak Thomas and Alex Philippidis for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Simulating Life: 4D Whole-Cell Model of a Minimal Bacterium

GEN, March 9, 2026

Safer Large DNA Insertion Moves Genetic Medicine Toward Scalability

By Fay Lin, PhD, GEN, March 11, 2026

Blood Biomarker Predicts Women’s Dementia Risk Up to 25 Years Early

GEN, March 10, 2026

StockWatch: Under Fire from FDA, uniQure Stock Roller-Coasters

By Alex Philippidis, GEN Edge, March 8, 2026

Touching Base Podcast

Hosted by Corinna Singleman, PhD

Behind the Breakthroughs

Hosted by Jonathan D. Grinstein, PhD

Hosted on Acast. See acast.com/privacy for more information.

AI for Scientists, FDA Reverses Course, and Advances in Cancer Therapeutics

Fri, 27 Feb 2026 14:18:15 GMT

In the industry news section of this week’s episode, we kick things off with Tamarind Bio’s efforts to develop user-friendly artificial intelligence tools for science researchers. Then we examine the impact of the U.S. Food and Drug Administration’s reversal on its earlier refusal to review Moderna’s mRNA vaccine for the flu, discuss Gilead’s acquisition of Arcellx to expand its cancer therapy pipeline, and dive into Takeda’s investment in Vir Biotech’s prostate cancer candidate. Then on the research front, we get into the science behind new protein-like polymers engineered to target and degrade some of cancer’s most challenging driver proteins. And we discuss a potential control switch for CAR T cells that could make these immunotherapies much safer.

Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, Uduak Thomas and Alex Philippidis for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Tamarind Bio Secures $13.6M Series A to Make AI More Accessible for Biology

By Fay Lin, PhD, GEN Edge, February 24, 2026

StockWatch: FDA Reversal Boosts Moderna, But Not Other Vaccine Companies

By Alex Philippidis, GEN Edge, February 21, 2026

Gilead to Acquire Arcellx for $7.8B, Adding Anito-Cel to Cancer Pipeline

By Alex Philippidis, GEN Edge, February 23, 2026

Astellas, Vir Biotechnology Launch Up-to-$1.7B Prostate Cancer Collaboration

By Alex Philippidis, GEN, February 26, 2026

New Protein-Like Polymers Target, Degrade “Undruggable” Proteins Driving Cancer

GEN, February 11, 2026

Drug-Controlled CAR T Cells May Enable Safer Immunotherapy

GEN, February 23, 2026

Touching Base Podcast

Hosted by Corinna Singleman, PhD

Behind the Breakthroughs

Hosted by Jonathan D. Grinstein, PhD

Hosted on Acast. See acast.com/privacy for more information.

Women in Science, Robotics, Automation, SLAS, and Lilly Updates

Fri, 13 Feb 2026 13:27:10 GMT

Women in Science Day (February 11) was the top of the list for discussion for GEN editors in this week’s podcast. They shared an anecdote on the history of the term “scientist”—hint it was coined for a woman. A modern scientist, Medra CEO Michelle Lee, discussed with GEN how the company is integrating robotics with AI for use in biological research. GEN attended SLAS this week and we got an update on the automation updates along with endeavors to increase the presence of women in biotech leadership. Finally, we get an update on Eli Lilly’s recent major deals followed by an update on Nektar Therapeutics clinical trial updates.

Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, Uduak Thomas and Alex Philippidis for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Data Is a Robotics Problem, Medra CEO Says Physical AI Will Transform Biology

By Fay Lin, PhD, GEN Edge, February 11, 2026

Robots on the Red Line: A Video Update from SLAS 2026

GEN, February 11, 2026

SLAS Highlights: AI Labs, Small-Molecule SPR, Protein Interaction Assays, and Paper Labware

By Uduak Thomas, GEN, February 11, 2026

SLAS Highlights: Opening Keynote Spotlights Novel Target in Genomically Unstable Tumors

By Uduak Thomas, GEN, February 11, 2026

Opentrons Uses Nvidia Tech to Build Training Data That Powers Physical AI in the Lab

By Uduak Thomas, GEN, February 9, 2026

Beyond Obesity: Lilly Inks Up to $11.25B in Cancer, Immune System Deals

By Alex Philippidis, GEN Edge, February 10, 2026

Lilly, Seamless Ink Up-to-$1.12B Hearing Loss Collaboration

By Alex Philippidis, GEN Edge, January 28, 2026

Touching Base Podcast

Hosted by Corinna Singleman, PhD

Behind the Breakthroughs

Hosted by Jonathan D. Grinstein, PhD

Hosted on Acast. See acast.com/privacy for more information.

Ex-CEO Behind Bars, 10x’s Clinical Ambitions, and Pharma’s AI Gambit

Fri, 30 Jan 2026 14:33:06 GMT

We kick off the very first episode of 2026 with a major legal development. This week, the former CEO of CytoDyn was sentenced to 30 months in prison, more than a year after being convicted on multiple charges including four counts of securities fraud, two counts of wire fraud, and three counts of insider trading. Also, we examine recent investments in artificial intelligence by several major drugmakers, and where they are hoping the technology can make an impact. Then, the latest from 10x Genomics and its plans to expand into clinical diagnostics through new collaboration. And for some research news, a new study that explores how functional forms of amyloid can create stable memories.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Ex-CytoDyn CEO Sentenced to 30-Month Prison Term on Fraud, Insider Trading

By Alex Philippidis, GEN, January 27, 2026

Pharma Bets Big on AI Platforms with Flurry of New Year Deals

By Fay Lin, PhD, GEN Edge, January 22, 2026

JPM: Nvidia Launches AI Collaborations with Eli Lilly, Thermo Fisher

By Alex Philippidis, GEN Edge, January 13, 2026

Clinical Ambitions: 10x Expands Beyond Research with Trio of Collaborations

By Alex Philippidis, GEN Edge, January 26, 2026

Chai’s the Limit for AI Antibody Designer After $130M Series B Funding

By Alex Philippidis, GEN Edge, December 16, 2025

Lilly Expands AI Ties to Insilico, from Customer to Drug Discovery Partner

By Alex Philippidis, GEN Edge, November 10, 2025

How Brain May Deliberately Form Amyloids to Turn Experiences Into Memories

GEN, January 26, 2026

Touching Base Podcast

Hosted by Corinna Singleman, PhD

Behind the Breakthroughs

Hosted by Jonathan D. Grinstein, PhD

Hosted on Acast. See acast.com/privacy for more information.

Editors’ Choice: Top Stories of 2025

Thu, 18 Dec 2025 18:12:44 GMT

In the final episode of 2025, the GEN team came together to reflect on some of the stories over the last year that they each found impactful. Some of the stories were covered in GEN’s December issue, but our editors took the time to discuss some topics in a bit more depth during the podcast. The discussion began with an update on the progress of AI use in drug discovery. Cell and gene therapy was a big topic with the positive outcome for Baby KJ, while Sarepta dealt with a rollercoaster of a year with their DMD treatment, Elevidys. Research and biotech in Africa are growing and the discussion ranged from challenges to promise in research and development on the continent. This year’s NIH budget cuts and impacted institutions rounded out the conversation.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, Phd, Kevin Davies, Phd, John Sterling, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

GEN Editors Reflect on Six of the Biggest Stories of the Year

By Alex Philippidis, Savannah Wiegel, Fay Lin, PhD, Kevin Davies, PhD, Uduak Thomas, and Julianna LeMieux, PhD, GEN, December 4, 2025

StockWatch: Sarepta Says Deaths of Two Elevidys Patients Posted on FDA Database Unrelated to Treatment

By Alex Philippidis, GEN Edge, August 10

StockWatch: As Prasad Exits FDA, Analysts See Benefit for Sarepta, CGT Stocks

By Alex Philippidis, GEN Edge, August 3

FDA Probes Death of Brazilian Boy Linked to Sarepta’s Elevidys

GEN Edge, July 27

Second DMD Patient Dies After Treatment with Sarepta Gene Therapy

By Alex Philippidis, GEN Edge, June 15

DMD Patient Dies After Treatment with Sarepta Gene Therapy

By Alex Philippidis, GEN Edge, March 18

From The Editor in Chief

John Sterling, December Issue of GEN

Gene Therapy in Africa

The State of CRISPR & Genome Editing Summit, June 11, 2025

TOP 50 NIH

By Alex Philippidis, GEN, December 4, 2025

FDA Cell & Gene Therapy roundtable: Cell and Gene Therapy Leaders Tell FDA: “Believe in American Solutions”

By Alex Philippidis, and Kevin Davies, PhD, GEN Edge, June 5, 2025

Scientists in NYC Rally to Defend and Stand Up for Science

By Corinna Singleman, GEN, March 10, 2025

Touching Base Podcast

Hosted by Corinna Singleman, PhD

Behind the Breakthroughs

Hosted by Jonathan D. Grinstein, PhD

Hosted on Acast. See acast.com/privacy for more information.

Lung Organoids, Autism and Sarcopenia Insights in Mice, and a Bidding War Ends

Thu, 04 Dec 2025 22:27:26 GMT

Stories on lung organoids and autism were some of the most read this week. We kicked things off by digging into recent breakthroughs in both areas including an automated method for manufacturing iPSC-derived lung organoids and how a combination of supplements reduced autism-linked behaviors in mice. Still on the topic of new research, we discussed how a protein in the extracellular matrix helps muscle stem cells repair aging muscles. In business news, the bidding war between Lundbeck and Alkermes over Avadel Pharmaceuticals has ended. We talk about the possible implications of Lundbeck’s decision to back out and next steps for Alkermes. Then we dive into Protego Biopharma’s recent fundraising round, and efforts to develop small-molecule pharmacological chaperones that modulate protein stability in disease.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Lung Organoids Generated in Bulk Using Stirred Bioreactor Technology

GEN, December 1, 2025

Autism-Linked Behaviors in Mice Reduced by Nutrient Trio

GEN, December 3, 2025

Muscle Stem Cells Bolstered by ECM Protein Tenascin-C

GEN, December 5, 2025

Protego Closes $130M Series B to Fund Pivotal Trial of AL Amyloidosis Candidate

By Alex Philippidis, GEN Edge, December 3, 2025

Lundbeck Ends Bidding War for Avadel, After Alkermes’ Up-to-$2.37B Offer

By Alex Philippidis, GEN Edge, December 1, 2025

Touching Base Podcast

Hosted by Corinna Singleman, PhD

Behind the Breakthroughs

Hosted by Jonathan D. Grinstein, PhD

Hosted on Acast. See acast.com/privacy for more information.

New Nasal Vaccines, Korro Stock Dips, J&J and Merck Acquisitions, and Dyno GATC

Thu, 20 Nov 2025 22:01:42 GMT

Nasal vaccines show new promise for human papillomavirus (HPV) to address cervical cancer and whooping cough. In business news, Korro's stock craters 81% as AATD interim Phase I/II results miss expectations. Additionally, Johnson & Johnson acquires Halda to expand their cancer pipeline while Merck acquires Cidara to boost antivirals. Lastly, the inaugural Genetic Agency Technology Conference (GATC) hosted by Dyno Therapeutics brought together a diverse group of researchers, entrepreneurs, and patient advocates to discuss the mission of genetic agency, or an individual’s ability to take action at the genetic level to live a healthier life.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Cervical Cancer May Be Treatable with Intranasal Nanogel Vaccine

GEN, November 15, 2025

Novel Nasal Spray Vaccine for Pertussis Shows Promise

By Corinna Singleman, PhD, GEN, November 12, 2025

StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia

By Alex Philippidis, GENEdge, November 16, 2025

J&J Expands Cancer Pipeline with $3B Halda Acquisition

By Alex Philippidis, GENEdge, November 18, 2025

Merck to Acquire Cidara for $9.2B, Bolstering Antiviral Pipeline

By Alex Philippidis, GEN, November 15, 2025

AI Meets Genetic Agency at Dyno GATC 2025

By Fay Lin, PhD, GENEdge, November 14, 2025

Genetic Agency on Display at GATC 2025

By Kevin Davies, PhD, and Fay Lin, PhD, GEN, November 13, 2025

Dyno GATC Announces AI Agents, Muscle Capsid, and Manufacturing Partner

By Fay Lin, PhD, GEN Edge, November 11, 2025

Touching Base Podcast

Hosted by Corinna Singleman, PhD

Behind the Breakthroughs

Hosted by Jonathan D. Grinstein, PhD

Hosted on Acast. See acast.com/privacy for more information.

uniQure Staggers at FDA, Recursion's Microglia Map, and Leadership Transitions

Fri, 07 Nov 2025 16:06:18 GMT

uniQure's “game changing” data announced in September, which showed significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy candidate AMT-130, may not be enough to secure FDA approval. We also discuss Recursion's pivotal leadership transitions, as Najat Khan, PhD, chief R&D officer and chief commercial officer, is set to take over as the company's CEO effective January 1. The AI drug developer has made big bets filling the biology data gap and recently announced a "Google Map of the brain" to advance neurodegenerative disease targets. In open-source AI for drug discovery, the release of the latest Boltz model, BoltzGen, advances the platform from structural predictions to the design of "any" therapeutic modality, all available for commercial use.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. 

Listed below are links to the GEN stories referenced in this episode of Touching Base: 

uniQure Staggers as FDA Questions Data for Huntington’s Gene Therapy Candidate

By Alex Philippidis, GEN Edge, November 3, 2025

StockWatch: uniQure Shares Reach Five-Year High on “Game Changing” Huntington’s Data

Alex Philippidis, GEN Edge, September 28, 2025

Gene Therapy Significantly Slows Huntington Disease Progression

GEN, September 24, 2025

Recursion, Roche Unveil Microglia Map of Neuro Disease Targets

By Alex Philippidis, GEN Edge, October 29, 2025

BoltzGen Democratizes AI Therapeutic Design, Expands Druggable Universe

By Fay Lin, PhD, GEN, October 27, 2025

The State of AI in Drug Discovery On Demand 

Touching Base Podcast 

Hosted by Corinna Singleman, PhD 

Behind the Breakthroughs 

Hosted by Jonathan D. Grinstein, PhD 

Hosted on Acast. See acast.com/privacy for more information.

Artificial Intelligence in the Emerald City and Targeting Colon Cancer Stem Cells

Fri, 24 Oct 2025 15:21:09 GMT

We are gearing up for our annual AI in Drug Discovery summit in a few days. So, for this episode, we focused on some recent AI news coverage. First, GEN senior editor Fay Lin, PhD, visited Seattle recently for some AI-focused meetings. She discusses her experiences in the Emerald City including an exclusive in-person interview with Nobel laureate, David Baker, PhD, on what’s real and what’s hype when it comes to using AI to design proteins de novo.  Then we discuss new research from University of California, San Diego, that used machine learning to identify networks of genes that could be targeted to reprogram cancer stem cells. We also go over some early studies that point to a possible drug candidate for colon cancer.  

Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. 

Listed below are links to the GEN stories referenced in this episode of Touching Base: 

Brunkow, Ramsdell, Sakaguchi Win Nobel Prize in Physiology or Medicine for Peripheral Immune Tolerance 

Uduak Thomas, GEN, October 6, 2025 

AI in Protein Design: Hype vs. Reality Explained by David Baker 

By Fay Lin, PhD, GEN, October 20, 2025 

Nobel Anniversary: David Baker Keynotes STEM Fundraiser by ARCS Foundation Seattle 

By Fay Lin, PhD, GEN, October 14, 2025 

AI Treatment Reprograms and Triggers Cancer Stem Cells to Self-Destruct 

GEN, October 20, 2025 

The State of AI in Drug Discovery Registration 

Touching Base Podcast 

Hosted by Corinna Singleman, PhD 

Behind the Breakthroughs 

Hosted by Jonathan D. Grinstein, PhD

Hosted on Acast. See acast.com/privacy for more information.

Nobel Prizes Announced and Breakthroughs for Huntington’s and Rare Diseases

Fri, 10 Oct 2025 13:16:41 GMT

Metal-organic frameworks and peripheral immune tolerance were the big winners of the Nobel prizes in chemistry, and in physiology or medicine, respectively. In this episode of the podcast, we discuss the winners and the impacts of their discoveries. Then we move over to some business news where we discuss a novel gene therapy for Huntington’s disease from uniQure that made waves recently. Early clinical trial data for AMT-130 showed that it could meaningfully slow the progression of the disease by as much as 75%. Also in business news, a new partnership involving Arbor Biotechnologies and Chiesi Group aims to develop gene editing therapies to target rare liver diseases.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Brunkow, Ramsdell, Sakaguchi Win Nobel Prize in Physiology or Medicine for Peripheral Immune Tolerance

Uduak Thomas, GEN, October 6, 2025

Metal-Organic Frameworks Win the 2025 Nobel Prize in Chemistry

Julianna LeMieux, PhD, GEN, October 8, 2025

Gene Therapy Significantly Slows Huntington Disease Progression

GEN, September 24, 2025

StockWatch: uniQure Shares Reach Five-Year High on “Game Changing” Huntington’s Data

Alex Philippidis, GEN Edge, September 28, 2025

Chiesi, Arbor Target Rare Liver Diseases in Up-to-$2.1B Gene Editing Collaboration

Alex Philippidis, GEN Edge, October 8, 2025

Touching Base Podcast

Hosted by Corinna Singleman, PhD

Hosted on Acast. See acast.com/privacy for more information.

BPI 2025 Debrief and Takeaways

Fri, 26 Sep 2025 15:31:32 GMT

GEN has been at the forefront of biotech and bioprocessing news for over 40 years. Last week, editor in chief, John Sterling and deputy editor in chief, Julianna LeMieux, PhD, attended BioProcess International (BPI). This annual meeting is a hallmark event for GEN, where we attend talks, speak with a multitude of bioprocess companies, and keep up to date on the latest products and news for the year. John and Julianna discuss their experience at this year’s event. Additionally, GEN held its first ever client appreciation reception this year at BPI and Julianna describes the atmosphere.

Join GEN editors John Sterling, Julianna LeMieux, PhD, and Corinna Singleman, PhD for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Boston’s Bioprocessing Buzz: GEN Reports Live from BPI 2025

Julianna LeMieux, PhD and John Sterling, GEN, September 18, 2025

Top 10 U.S. Biopharma Clusters 2025

Alex Philippidis, GEN, August 1, 2025

Top 10 Contract Development and Manufacturing Organizations 2025

Alex Philippidis, GEN, September 15, 2025

Touching Base Podcast

Hosted by Corinna Singleman, PhD

Hosted on Acast. See acast.com/privacy for more information.

Developing New Therapies Through Partnership, Electricity, and Immunotherapy

Fri, 05 Sep 2025 13:50:09 GMT

Novartis has agreed to license and develop Arrowhead Pharmaceuticals’ preclinical stage small interfering RNA (siRNA) therapy ARO-SNCA, a potential treatment for Parkinson’s disease and other synucleinopathies, plus additional targets. Two stories this week covered very different types of cell reprogramming techniques for therapy development. The first approach may overcome the time delays and safety risks of traditional immunotherapies, especially for patients with aggressive, late-stage disease. Meanwhile, electrical stimulation of macrophages could represent a new therapy to boost the body’s own repair processes in a range of injury and disease situations. Finally, Eli Lilly saw its shares climb 5% this past week after announcing that its history-making oral obesity candidate, orforglipron, aced the Phase III ATTAIN-2 trial.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

The State of Biotech Summit Registration

Novartis Commits Up to $2.2B toward Developing Arrowhead siRNA Therapy

Alex Philippidis, GEN Edge, September 2, 2025

Off-the-Shelf Immunotherapy Demonstrates Multipronged Attack Against Cancer

GEN, August 29, 2025

Human Macrophages “Reprogrammed” by Electrical Stimulation to Encourage Faster Healing

GEN, September 2, 2025

StockWatch: Analysts See $10B+ in Sales for Lilly Oral GLP-1

Alex Philippidis, GEN Edge, September 1, 2025

Touching Base Podcast

Hosted by Corinna Singleman, PhD

Behind the Breakthroughs

Hosted by Jonathan D. Grinstein, PhD

Hosted on Acast. See acast.com/privacy for more information.

Stem Cells in Space and AI for Nanoparticles and Peptide Design

Fri, 22 Aug 2025 14:35:18 GMT

This week’s episode explores two frontiers: space travel and artificial intelligence. First, we discuss a study testing whether mouse sperm cryopreserved and stored in the International Space Station could still produce healthy offspring back on Earth. It’s a question with real implications for the future of deep space missions and even space tourism. Then, we turn to recent advances in AI. We talk about a machine-learning model trained to predict more effective nanoparticles for delivering RNA vaccines and therapies. Also, we learn about an AI model that designs peptides for challenging targets in cancer and neurodegenerative disease without needing detailed protein structures.

Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

The State of Biotech Summit Registration

Space Station Stem Cells Successfully Produce Healthy Mice

GEN, August 18, 2025

COMET's Rocket Speed: AI-Designed Nanoparticles Accelerate mRNA Therapies

GEN, August 18, 2025

Protein Language Model Hits Undruggable Targets, No Structure Required

By Fay Lin, PhD GEN, August 14, 2025

Touching Base Podcast

Hosted by Corinna Singleman, PhD

Behind the Breakthroughs

Hosted by Jonathan D. Grinstein, PhD

Hosted on Acast. See acast.com/privacy for more information.

Reversing Parkinson’s in Mice, Protecting Primates from HIV, Top 10 Biotech Clusters, and Sarepta

Fri, 08 Aug 2025 16:15:01 GMT

This episode of GEN's Touching Base spotlights the unexpected relationship between breathing low oxygen and restoration of neuron function in a mouse model of Parkinson’s disease. In addition, a single gene therapy injected at birth now offers lasting protection from HIV in infant rhesus macaques. Rounding out our episode, we discuss key factors shaping this year’s A-List of Top 10 U.S. Biopharma Clusters and recap the regulatory conflict surrounding Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) gene therapy, Elevidys®—including the departure of Vinay Prasad, MD, the FDA official behind the agency’s brief get-tough approach.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

GLP-1 Drug Semaglutide Linked to Reduced Muscle Strength in Mice

GEN, August 6, 2025

Out of Thin Air: Hypoxia Reverses Parkinson’s Symptoms in Mice

By Fay Lin, PhD GEN, August 6, 2025

Early Gene Therapy Provides Lasting HIV Protection in Newborn Primates

GEN, July 30, 2025

StockWatch: As Prasad Exits FDA, Analysts See Benefit for Sarepta, CGT Stocks

By Alex Philippidis, GEN Edge, August 3, 2025

Sarepta to Resume Shipping DMD Gene Therapy to Ambulant Patients

By Alex Philippidis, GEN Edge, July 28, 2025

Sarepta Under Scrutiny, AstraZeneca’s Big Bet, and AI vs. IDRs

By Alex Philippidis, Uduak Thomas, Fay Lin, PhD, Corinna Singleman, PhD, GEN, July 25, 2025

About Face: Sarepta to Pause Elevidys Shipments Temporarily

By Alex Philippidis, GEN Edge, July 21, 2025

Touching Base Podcast

Hosted by Corinna Singleman, PhD

Behind the Breakthroughs

Hosted by Jonathan D. Grinstein, PhD

The State of Biotech Summit Registration

Hosted on Acast. See acast.com/privacy for more information.

Sarepta Under Scrutiny, AstraZeneca’s Big Bet, and AI vs. IDRs

Fri, 25 Jul 2025 02:32:43 GMT

Sarepta has temporarily paused shipments of Elevidys, its FDA-approved treatment for Duchenne muscular dystrophy. In this episode of GEN's Touching Base, we discuss the company’s response to the tragedies associated with its DMD therapy as well as with a new therapy for limb-girdle muscular dystrophy. Also in this episode, big updates from AstraZeneca including a $50 billion investment in U.S. manufacturing and R&D, a heartwarming story about preventing mitochondrial disease involving eight babies from the U.K., and from the lab of Nobel Prize winner David Baker, PhD, AI that designs drugs for previously “undruggable” proteins.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

About Face: Sarepta to Pause Elevidys Shipments Temporarily

By Alex Philippidis, GEN Edge, July 21, 2025

StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies

By Alex Philippidis, GEN Edge, July 20, 2025

Sarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient Deaths

By Alex Philippidis, GEN Edge, July 16, 2025

AstraZeneca Commits $50B More to U.S. Manufacturing, R&D Projects

By Alex Philippidis, GEN Edge, July 22, 2025

AstraZeneca’s New $300M Plant Provides Control of Cell Therapy Production

By Gareth John Macdonald, GEN, May 14, 2025

Beyond Baby KJ: Next Steps in Manufacturing Genome Editing Cures

GEN Live, July 30, 2025

Mitochondrial Disease Milestone: Eight Babies Born Free of Disease via Pronuclear Transfer

By Julianna LeMieux, PhD GEN, July 16, 2025

Undruggable No More: AI Hits Disordered Proteins, Unlocks Therapy Targets

By Fay Lin, PhD GEN, July 18, 2025

Hosted on Acast. See acast.com/privacy for more information.

Merck Acquires Verona, Virtual Cell Challenge, Gene Therapy Restores Hearing

Fri, 11 Jul 2025 13:05:17 GMT

Merck & Co. has acquired Verona Pharma for $10 billion in a deal designed to expand the pharma giant’s portfolio of cardio-pulmonary disease treatments. In a step toward virtual cell benchmarking, the Arc Institute has launched the Virtual Cell Challenge to evaluate the ability of transcriptome AI models to generalize to new cell contexts for therapeutic applications. Fujifilm rebrands life science companies to position itself as a drug development leader. Additionally, AAV-OTOF gene therapy shows promise in restoring hearing loss while a new proteomics tool gleams insight into telomere repair. We wrap up our episode with highlights from BIO 2025, as FDA Commissioner Martin Makary, MD, shared his vision for a “New FDA” focused on accelerating drug applications, industry partnerships, and applying AI.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Merck to Acquire Verona Pharma for $10B, Adding Fast-Growing COPD Drug

By Alex Philippidis, GEN Edge, July 9, 2025

Arc Institute Launces Virtual Cell Challenge to Accelerate AI Model Development

By Fay Lin, PhD, GEN Edge, June 26, 2025

End-to-End: Fujifilm Rebrands Life Sciences Companies, Positioning Itself as Drug Development Cycle Leader

By Alex Philippidis, GEN Edge, July 8, 2025

AAV-OTOF Gene Therapy Trial Restores Hearing in Both Children and Adults

By GEN, July 7, 2025

Proteomics Tool Sheds Light on Cancer Cells’ Telomere Repair Tactics

By GEN, July 7, 2025

Makary Calls for “New FDA” at BIO; Defends Agency’s Spring Job Cuts

By Alex Philippidis, GEN Edge, June 18, 2025

Cell and Gene Therapy Leaders Tell FDA: “Believe in American Solutions”

By Kevin Davies, PhD, and Alex Philippidis, GEN Edge, June 5, 2025

Behind the Breakthroughs Podcast

Hosted by Jonathan D. Grinstein, PhD

Hosted on Acast. See acast.com/privacy for more information.

BIO 2025, Huge Virtual Cell Dataset, AI-Designed De Novo Proteins

Wed, 18 Jun 2025 19:59:45 GMT

Acast

BIO 2025, Huge Virtual Cell Dataset, AI-Designed De Novo Proteins

BIO 2025 is off and running. GEN editors discuss the size and scope of the bustling conference hall and share excitement about the week’s talks and panels. News from BIO includes the announcement of Lilly’s acquisition of Verve Therapeutics. Editors discuss the implications of industry-backed therapeutics amid cautious investors and public sentiment. In the realm of AI, Xaira Therapeutics, a $1 billion-backed AI drug discovery unicorn, has capped its first year by releasing the largest publicly available Perturb-seq dataset to support its virtual cell initiative. Additionally, AlphaDesign, a new AI-driven framework, accelerates the creation of functional de novo proteins, moving protein design toward custom therapeutics and precision medicine.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Uduak Thomas, and Fay Lin, PhD, for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base

Lilly to Acquire Verve Therapeutics for Up to $1.3B

By Alex Philippidis, GEN Edge, June 17, 2025

Second DMD Patient Dies After Treatment with Sarepta Gene Therapy

By Alex Philippidis, GEN Edge, June 15, 2025

Danon Disease Patient Dies in Rocket Gene Therapy Trial

By Alex Philippidis, GEN Edge, May 27, 2025

Xaira Therapeutics Releases Largest Perturb-Seq Dataset to Power the Virtual Cell

By Fay Lin, GEN Edge, June17, 2025

AI-Designed Proteins Created De Novo with New AlphaDesign

GEN, June 17, 2025

Hosted on Acast. See acast.com/privacy for more information.

Rocket’s Gene Therapy Trial Paused, Boltz-2 Open Source, Plasma Swap Rewinds Aging

Fri, 06 Jun 2025 13:14:10 GMT

A gene therapy clinical trial for Danon disease run by Rocket Pharmaceuticals has been suspended following the death of a patient. MIT and Recursion have released Boltz-2, an open-source tool that predicts molecular binding affinity at newfound speed and accuracy, aiming to democratize commercial drug discovery. Intellia Therapeutics saw its stock nosedive late last week after a patient in its Phase III trial of the CRISPR-based therapy experienced non-lethal liver toxicity. In other news, a therapeutic plasma exchange regimen combined with intravenous immunoglobulin reduced some biomarkers of biological age in humans. Sanofi has agreed to acquire Blueprint Medicines for up to $9.5 billion, and a universal CAR T cell therapy was produced by applying CRISPR gene editing to cells donated by healthy individuals.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. 

Listed below are links to the GEN stories referenced in this episode of Touching Base

Danon Disease Patient Dies in Rocket Gene Therapy Trial

By Alex Philippidis, GEN, May 27, 2025

Boltz-2 Released to Democratize AI Molecular Modeling for Drug Discovery

By Fay Lin, PhD, GENEdge, June 6, 2025

StockWatch: Intellia Stumbles on News of Patient’s Severe Liver Toxicity

By Alex Philippidis, GEN, May 30, 2025

The State of CRISPR Summit Registration

https://bit.ly/CRISPR25

Plasma Exchange in Humans Reduces Biological Age by Over Two Years

GEN, June 1, 2025

Sanofi to Acquire Blueprint Medicines for Up to $9.5B

By Alex Philippidis, GEN Edge, June 2, 2025

"Universal" CAR-T Immunotherapy Targets Relapsed/Refractory Blood Cancers

GEN, May 30, 2025

Hosted on Acast. See acast.com/privacy for more information.

Customized CRISPR for KJ, 10x and Illumina Lawsuits, Regeneron Bags 23andMe

Thu, 22 May 2025 16:38:20 GMT

A baby, named KJ, has become the first patient to be treated with a personalized CRISPR therapy to address a severe metabolic disorder. We discuss this story—one of the biggest science/medical stories from ASGCT 2025—and talk about the family and scientists at its center. In other news, laboratory-evolved CRISPR-associated bacterial transposases are being used to insert healthy genes into human cells. On the business front, 10x Genomics settles with Bruker and Vizgen while Illumina sues Element Biosciences for patent infringement. Also, trouble for Prime Medicine as the company pivots its pipeline and downsizes, and after months of speculation about its fate, 23andMe is acquired by Regeneron.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base

ASGCT 2025: World’s First Patient Treated with Personalized CRISPR Therapy

By Fay Lin, PhD, GEN, May 15, 2025

EvoCAST Harnesses CRISPR-Linked Bacterial Transposases to Insert Genes Into Human Cells

GEN, May 18, 2025

eePASSIGE Engineers Gene-Sized Edits in Human Cells

GEN, June 10, 2024

Illumina Sues Element Biosciences, Alleging Infringement of Flow Cell, Imaging Patents

By Alex Philippidis, GEN Edge, May 18, 2025

10x Settles Bruker, Vizgen Patent Lawsuits

By Julianna LeMieux, PhD, and Alex Philippidis, GEN, May 18, 2025

Prime Medicine Chops 25% of Workforce, Pivots Pipeline as CEO Quits

By Alex Philippidis, GEN Edge, May 19, 2025

Regeneron to Acquire 23andMe with Winning $256M Bid

GEN, May 19, 2025

Hosted on Acast. See acast.com/privacy for more information.

Insights into COVID-19’s Origins, Recursion Reverses Course, and AACR Stands Up for Cancer Research

Fri, 09 May 2025 16:27:51 GMT

The exact origins of SARS-CoV-2 are still something of a mystery, but new research may bring scientists one step closer to an explanation for how the virus reached Wuhan. Also in the episode, we dive into GEN’s coverage of the annual AACR meeting including how the community is navigating massive research budget cuts. Then we discuss a potential colorectal cancer therapy using CRISPR-edited tumor infiltrating lymphocytes and a method for delivering protein therapies and gene editors using engineered vesicles. Lastly, in business news, Recursion rethinks its pipeline, the FDA gives Abeona’s gene therapy a chance, and Bristol Myers Squibb execs open up on artificial intelligence.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Julianna LeMieux, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

AACR 2025: A Video Update from Chicago

By Julianna LeMieux, PhD and Damian Doherty, GEN, April 29, 2025

Hope and Headwinds at AACR in Chicago

By Damian Doherty, GEN, April 29, 2025

Senator Tammy Baldwin Supports Science in AACR Speech

By Julianna LeMieux, PhD, GEN, April 29, 2025

CRISPR-Edited TILs Fight Advanced Colorectal Cancer in Patients

By GEN, May 4, 2025

Engineered Extracellular Vesicles Could Deliver Gene Editors, Therapeutic Proteins to Cells

By GEN, April 30, 2025

SARS-CoV-2 Likely Spread Through Wildlife Trade, Not Bat Migration

By GEN, May 7, 2025

Chatting with Author David Quammen about SARS-CoV-2 Will Leave You “Breathless”

Originally aired: November 16, 2022

Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus

By Alex Philippidis, GEN Edge, May 5, 2025

StockWatch: Second Time’s the Charm for Abeona’s Gene Therapy

By Alex Philippidis, GEN Edge, May 4, 2025

Predict First: BMS Executives Discuss Company’s AI Approach

By Alex Philippidis, GEN Edge, March 26, 2025

Hosted on Acast. See acast.com/privacy for more information.

Navigating Biotech’s New Normal, Applying AI to Cas9 Enzymes, and Sequencing Generations

Fri, 25 Apr 2025 16:31:34 GMT

The seismic changes made by the current administration in the United States continue to impact the scientific community. The business news segment of this week’s episode covers the effects of job cuts on biotech, Roche’s manufacturing and R&D plans amid tariff threats, and shares an update on Eli Lilly’s diabetes pill. Also, in honor of DNA Day, we reminisce about how far the field has come since the discovery of the structure of DNA and the completion of the Human Genome Project. We also talk about today’s DNA-related advances that use machine learning to design tailored Cas9 proteins and multiple sequencing technologies to study mutation rates in four generations of the same family.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

After Job Cuts, “We’re Entering a Very New Territory for Biotech.

By Alex Philippidis, GEN Edge, April 17, 2025

Roche Commits $50B to U.S. Manufacturing, R&D as Tariffs Loom

By Alex Philippidis, GEN Edge, April 22, 2025

StockWatch: Investors Hungry for Lilly after Diabetes Pill Aces Phase III Trial

By Alex Philippidis, GEN Edge, April 20, 2025

Machine Learning Engineers Bespoke Cas9 Enzymes for Gene Editing

By Fay Lin, PhD, GEN, April 22, 2025

Multi-Platform Sequencing Study of Four Generations Sheds Light on Mutation Rates

GEN, April 23, 2025

Hosted on Acast. See acast.com/privacy for more information.

Discussing De-Extinction, Trump’s Tariffs Touch Biopharma, and Reports from Recent Travels

Fri, 11 Apr 2025 17:22:28 GMT

Are Dire Wolves really back? We give our take on Colossal Biosciences’ latest announcement about the de-extinction of Dire Wolves including some thoughts on their approach and some of the broader implications of their work. In other stories, we discuss the early impact of the Trump administration’s tariffs on biotech as well as the growing alarm in the scientific community in the wake of sweeping layoffs and leadership departures at the FDA, CDC, and NIH. We also share news from recent scientific conferences and meetings that we’ve attended as well as an interesting study that used human cell maps to shed new light on pediatric bone cancer.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base.

Plex Research Partners with Ginkgo Bioworks to Apply AI-Based Search Engine to Drug Discovery

By Uduak Thomas, GEN, April 8, 2025

Danaher-IGI Beacon for CRISPR Cures Celebrates One-Year Anniversary

By Fay Lin, PhD, GEN, March 28, 2025

Human Cell Maps Uncover Insights in Pediatric Bone Cancer

By Fay Lin, PhD, GEN, April 10, 2025

StockWatch: Biopharma Funds Tumble with Wall Street as Industry Spared from Worst of Tariffs—for Now

By Alex Philippidis, GEN Edge, April 6, 2025

FDA, NIH, CDC Stagger as HHS Axe Falls, Eliminating 10,000 Jobs

By Alex Philippidis, GEN Edge, April 1, 2025

Industry Voices Alarm as Peter Marks Departs FDA

By Kevin Davies, PhD, and Alex Philippidis, GEN Edge, March 30, 2025

The State of Multiomics & NGS 2025

Broadcast Date: Wednesday, April 23, 2025

Resurrection Genomics: A Conversation with Colossal’s Chief Biology Officer Eriona Hysolli

The State of Omics 2024, April 17, 2024

Hosted on Acast. See acast.com/privacy for more information.

Dravet Gene Therapy Tested in Mice, Sarepta’s Setback, and AstraZeneca Updates

Fri, 28 Mar 2025 17:22:02 GMT

Gene therapies take center stage in this week’s episode. We discuss a potential gene replacement therapy for people with Dravet Syndrome that scientists have tested in mice with good results and highlight some recent progress from two editing companies. We also break down the recent news from Sarepta about the death of a patient after treatment with its gene therapy for Duchenne muscular dystrophy. In other stories, new data reveals a nonviral method for introducing transgenes into human primates and AstraZeneca steps up R&D in China with new drug, vaccine, and healthcare partnerships in the billions of dollars.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Julianna LeMieux, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base

Gene Therapy Tested in Mice Offers New Hope for People with Dravet Syndrome

By Uduak Thomas, GEN, March 19, 2025

DMD Patient Dies After Treatment with Sarepta Gene Therapy

By Alex Philippidis, GEN Edge, March 18, 2025

PiggyBac Transposon System Creates Transgenic Cynomolgus Monkeys

By Julianna LeMieux, PhD, GEN, March 26, 2025

From Tools to Trials: Editing Therapy Companies Pivot to Development

By Alex Philippidis, PhD, GEN Edge, March 20, 2025

AstraZeneca Commits up to $11B+ to Chinese Collaborations, Beijing R&D Hub

By Alex Philippidis, PhD, GEN Edge, March 21, 2025

Hosted on Acast. See acast.com/privacy for more information.

Genetic Engineering at Asilomar, Stand Up for Science, and Francis Collins

Fri, 14 Mar 2025 13:42:59 GMT

GEN editors discuss both the news and history of DNA and genetic engineering. We present a recap of the 50th anniversary Asilomar conference, delving into some of the history from the 1975 Asilomar conference and relating to the current discussions around genetic engineering. Science has been under fire recently and many people attended the Stand Up for Science Rally at one of a few dozen locations across the United States. One of the speakers at the rally in Washington, DC, was former NIH director Francis Collins, MD, PhD, a key member of the Human Genome Project. We discuss some of his career in this episode.

Join GEN's managing editor Corinna Singleman, PhD, editor in chief John Sterling, and editorial director Kevin Davies for a discussion of DNA news and history.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Scientists in NYC Rally to Defend and Stand Up for Science

By Corinna Singleman, PhD, GEN, March 10, 2025

Former NIH Director Francis Collins Praises the Institution as He Abruptly Departs After Three Decades

By Kevin Davies, PhD, GEN, March 3, 2025

Hosted on Acast. See acast.com/privacy for more information.

AI Models Writing DNA and Designing Enzymes, Some Pre-AGBT News

Fri, 28 Feb 2025 16:10:45 GMT

In honor of Rare Disease Day, we discuss news from Healx, a clinical-stage biotech, which has dosed the first patient in a Phase II trial of its new drug for neurofibromatosis type 1. In the world of AI, the Arc Institute in collaboration with Nvidia has dropped Evo 2, the “largest publicly accessible AI model for biology to date,” for designing genomes. Additionally, new work from Nobel Laureate, David Baker, uses AI to generate enzymes from scratch. We also dig into the big announcements from Illumina and Roche that got the community buzzing ahead of this year’s AGBT meeting.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Healx Candidate, SpringWorks Therapy Expand NF1 Treatment Options

By Alex Philippidis, GEN Edge, February 25, 2025

Arc Institute’s AI Model Evo 2 Designs the Genetic Code Across All Domains of Life

By Fay Lin, PhD, GEN Edge, February 19, 2025

AI-Driven Protein Design Produces Enzyme that Mimics Natural Hydrolase Activity

By Corinna Singleman, PhD, GEN, February 13, 2025

Illumina Unveils Spatial Technology Days Before AGBT Meeting

By Julianna LeMieux, PhD, GEN, February 19, 2025

StockWatch: Illumina Tumbles on Q4 Results, China Retaliation

By Alex Philippidis, GEN Edge, February 8, 2025

Roche Announces SBX Technology, Creates Sequencing Buzz

By Julianna LeMieux, PhD, GEN, February 21, 2025

StockWatch: NIH Indirect Cost Cuts Shake Tools Stocks

By Alex Philippidis, GEN Edge, February 17, 2025

Hosted on Acast. See acast.com/privacy for more information.

Recursion Clinical Trial, CRISPR Delivery methods, preclinical Cas12 use, Gene Editing in AgBio, Top 10 Takeover Targets

Fri, 14 Feb 2025 17:31:38 GMT

Season 2 Episode 1 (February 14, 2025): This week, the GEN editors discussed some interesting and developing stories around AI, including an in depth dialogue about what Recursion has been doing lately. They also discussed gene editing updates in delivery systems, Cas12 preclinical work, and AgBio. The discussion was rounded out with a look forward into takeover targets for 2025.

Featuring Alex Philippidis (Senior Business Editor, GEN), Fay Lin, PhD, (Editor, GEN Biotechnology), Uduak Thomas (Senior Editor, GEN), and moderated by Corinna Singleman, PhD, (Managing Editor, GEN and IPM)

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

As Pipeline Advances, Recursion Expands AI Focus to Clinical Trials

By Alex Phillipidis, GEN, Jan 30, 2025.

Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain Disease

By Fay Lin, PhD, GEN Edge, Feb 5, 2025.

AAV Delivered NanoCas CRISPR System Edits Muscle in Non-Human Primates

By GEN, Feb 3, 2025.

Next-Gen Cas12a System Enables Precise Single and Multiplexed Gene Editing in Cancer

By Corinna Singleman, PhD, GEN, Jan 30, 2025.

AgBio Companies Embrace Gene Editing for Stronger Food Future

By Uduak Thomas, GEN Feb issue, Feb 3, 2025.

Top 10 Takeover Targets of 2025

By Alex Phillippidis, GEN, Feb 3, 2025.

Hosted on Acast. See acast.com/privacy for more information.

DNA Day: Deep Dive

Fri, 26 Apr 2024 13:25:40 GMT

Episode 19 (April 26, 2024): This week, the GEN editors celebrated DNA Day by sharing some stories about their favorite observations and applications of DNA research.

Featuring Kevin Davies, PhD (Editorial Director, GEN), John Sterling (Editor in Chief, GEN), Uduak Thomas (Senior Editor, GEN), Alex Philippidis (Senior Business Editor, GEN), Fay Lin, PhD (Senior Editor, GEN Biotechnology), Jonathan Grinstein, PhD (Senior Editor, GEN), and moderated by Corinna Singleman, PhD (Managing Editor, GEN and IPM).

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

The Life and Times of Rosalind Franklin

GEN Webinar presented by Matthew Cobb, PhD, Oct 16, 2020.

"Life Story"

BBC film (1987).

Nobel Winner Svante Pӓӓbo Discovered the Neandertal in Our Genes

By Daniela Mocker, Scientific American, Oct 4, 2022.

“Svante Pӓӓbo, reader of the Neanderthal genome”

Wielgus, Danielewski, and Walkowiak, Acta Physiol, Nov 23, 2022.

Colossal’s Woolly Mammoth Project Advances as Elephant iPSCs Clear Milestones

GEN, Mar 7, 2024.

The State of Omics 2024

GEN Summit.

“Genetic Ancestry Testing What is it and Why is it Important?”

Jorde and Bamshad, JAMA, Mar 27, 2020.

A Leading Cause of Autism Spectrum Disorders May Be Prevented by Novel Approach

GEN, May 21, 2023.

AI Finds Autism-Causing Mutations in “Junk” DNA

GEN, May 28, 2024.

Pollution and Stress Alter Brain Development and Social Behavior in Male Mice

GEN, Aug 3, 2022.

“Mechanistic Basis of Resistance to PCBs in Atlantic Tomcod from the Hudson River”

Wirgin, et al., Science, Mar 11, 2011.

Hosted on Acast. See acast.com/privacy for more information.

How Biotechs Are Plugging AI into Drug Discovery Problems

Fri, 19 Apr 2024 13:46:48 GMT

Episode 18 (April 19, 2024):

Biology’s exploding data streams continue to leverage artificial intelligence (AI) tools to streamline drug development. How do we define AI in drug discovery? Who are notable players in the space? How do humans fit into these growing computational pipelines?

This week, Jonathan Grinstein, PhD (Senior Editor, GEN) and Fay Lin, PhD (Senior Editor, GEN Biotechnology) unpack one of the fastest growing topics in the biotech field, AI in drug discovery.

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

The Difference Is the Data: Drug Discovery’s AI Revolution

By Fay Lin, PhD, GEN Biotechnology, April 18, 2024

Archimedes’ Box: Diagonal Therapeutics Raises $128 Million to Discover Agonist Antibodies

By Jonathan Grinstein, PhD, GEN Edge, April 3, 2024

Generate:Biomedicines Raises Largest Biotech Series C of 2023

By Jonathan Grinstein, PhD, GEN Edge, September 14, 2023

Alex Zhavoronkov Aims to Take Over the Drug Development World with AI

By Jonathan Grinstein, PhD, GEN Edge, June 20, 2023

Diffusion Evolution: New Artificial intelligence Models Break Barriers in Protein Design

By Fay Lin, PhD, GEN Biotechnology, October 16, 2023

Hosted on Acast. See acast.com/privacy for more information.

Launch of Nvelop Therapeutics for Delivery of Genetic Cargo, AACR Recap

Fri, 12 Apr 2024 17:50:03 GMT

Episode 17 (April 12, 2024):

This week, the GEN editors discuss the launch of Nvelop Therapeutics, a new start-up leveraging approaches developed by gene editing pioneers David Liu, PhD, and J. Keith Joung, MD, PhD, to advance delivery of genetic cargo. The GEN editors also recap highlights from the American Association for Cancer Research (AACR) annual meeting held in San Diego, California.

Featuring Uduak Thomas (Senior Editor, GEN), Alex Philippidis (Senior Business Editor, GEN), Julianna LeMieux, PhD (Deputy Editor-in-Chief, GEN), and Jonathan Grinstein, PhD (Senior Editor, GEN), and moderated by Fay Lin, PhD (Senior Editor, GEN Biotechnology)

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

The State of Omics 2024 Registration

GEN Summit

Cloaking Device: Liu, Joung Launch $100M Nvelop Therapeutics to Advance Delivery of Genetic Cargo

By Alex Philippidis, GEN Edge, April 9, 2024

Bertozzi, Regev, and More Inspire During the Opening Plenary Session of AACR

By Julianna LeMieux, PhD, GEN, April 8, 2024

AACR 2024: Aviv Regev Shows How Single-Cell Atlases Foster New Axis to Genentech’s Drug Discovery

By Jonathan Grinstein, PhD, GEN, April 8, 2024

AACR 2024: A Video Update from San Diego

By Julianna LeMieux, PhD, and Jonathan Grinstein, PhD, GEN, April 8, 2024

A Video Update from Day Two of the AACR Meeting

By Julianna LeMieux, PhD, and Jonathan Grinstein, PhD, GEN, April 9, 2024

AACR 2024: EpiBiologics Advances Degraders of Membrane-Bound Proteins

By Jonathan Grinstein, PhD, GEN, April 8, 2024

Celebrating National Robotics Week

By Uduak Thomas, GEN, April 12, 2024

Hosted on Acast. See acast.com/privacy for more information.

Dried Blood COVID Dx, Cryo-Shocked Tumor Cell Delivery Vehicles, Verve Halts Trial, Iambic Starts Trial, and Diagonal Therapeutics Launches

Fri, 05 Apr 2024 13:56:47 GMT

Episode 16 (April 5, 2024): This week, the GEN editors discussed deep proteome profiling of home-sampled dried blood spots to assess the effects of SARS-CoV-2 in mildly symptomatic or asymptomatic, rapid liquid nitrogen treatment for converting tumor cells into carriers for gene editing tools that target cancer in vivo, Verve Therapeutics’ pausing of a clinical trial due to a serious adverse event, Iambic Therapeutics’ advancement of its first AI-designed candidate into the clinic, and the launch of Diagonal Therapeutics to find agonist antibodies for heteromeric receptor complexes.

Featuring Uduak Thomas (Senior Editor, GEN), Alex Philippidis (Senior Business Editor, GEN), Jonathan Grinstein, PhD, (Senior Editor, GEN), and moderated by Corinna Singleman, PhD, (Managing Editor, GEN and IPM)

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

The State of Omics 2024 Registration

GEN Summit

COVID-19 Infections Detected in Dried Blood Spots via At-Home Proteomic Profiling

By GEN, April 2, 2024.

CRISPR-Cas9 Targets Lung Cancer Using Cryo-Shocked Tumor Cells

By GEN, March 31, 2024.

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers

By Alex Philipidis, GEN, April 3, 2024.

Archimedes' Box: Diagonal Therapeutics Raises $128 Million to Discover Agonist Antibodies

By Jonathan D. Grinstein, PhD, GEN Edge, April 3, 2024.

Hosted on Acast. See acast.com/privacy for more information.

AI in Drug Discovery and Precision Medicine: Nvidia GTC and Precision Med TRI-CON

Fri, 29 Mar 2024 15:22:01 GMT

Episode 15 (March 29, 2024): From the expansion of Nvidia's generative artificial intelligence (AI) platform for drug discovery to AI notetakers that coach doctors to be more human, the GEN editors discuss the latest news in AI from two conferences in California: Nvidia GTC (San Jose) and Precision Med TRI-CON (San Diego).

Featuring Alex Philippidis (Senior Business Editor, GEN), Fay Lin, PhD (Senior Editor, GEN Biotechnology), Jonathan D. Grinstein, PhD (Senior Editor, GEN), moderated by Corinna Singleman, PhD (Managing Editor, GEN and IPM).

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

GTC 2024: Nvidia Highlights AI ‘Revolution’ in Drug Discovery, Genomics

By Alex Philippidis, GEN, March 19, 2024.

GTC 2024: Nvidia’s Quantum Expansion Runs through the Cloud

By Alex Philippidis, GEN, March 20, 2024.

Machines Bring Efficiency…and Empathy? Eric Topol Talks AI in Precision Medicine

By Fay Lin, PhD, GEN Edge, March 28, 2024.

Hosted on Acast. See acast.com/privacy for more information.

Optimizing Nanoparticles and Messenger RNAs with Multiple “Tails”

Fri, 22 Mar 2024 16:29:38 GMT

Episode 14 (March 22, 2024): This week, the GEN editors cover identifying receptors and proteins for cellular uptake and intracellular processing of nanoparticles, and a new mRNA structure by adding multiple “tails” to the molecules that boosted mRNA activity levels in cells by 5 to 20 times.

Featuring Jonathan D. Grinstein, PhD, (Senior Editor, GEN), Uduak Thomas (Senior Editor, GEN), and moderated by Fay Lin, PhD, (Senior Editor, GEN Biotechnology)

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

Nanoparticle Uptake Screen Informs Nanomedicine Design

By GEN, March 19, 2024.

mRNA Therapeutics May Act Longer If Given Multiple Tails

By GEN, March 22, 2024

Hosted on Acast. See acast.com/privacy for more information.

NanoString Finds a Buyer, Slide Tags Enter in Early Access as Curio Trekker, Cellares Unveils Cell Therapy Manufacturing Platform

Fri, 15 Mar 2024 14:06:29 GMT

Episode 13 (March 15, 2024): This week, the GEN editors discussed business news from NanoString, Curio, and Cellares.

Featuring Alex Philippidis (Senior Business Editor, GEN), Uduak Thomas (Senior Editor, GEN), Jonathan Grinstein, PhD, (Senior Editor, GEN), and moderated by Corinna Singleman, PhD, (Managing Editor, GEN and IPM).

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

The State of Omics 2024 Registration

GEN Summit

NanoString Agrees to be Acquired by Investment Firm for $220M

By GEN, March 11, 2024.

Curio Begins Testing Commercial Spatial Barcoding Technology for Single Cell Sequencing

By GEN, March 12, 2024

Cellares Unveils Clinically-Compliant Cell Therapy Manufacturing Platform

By Jonathan D. Grinstein, PhD, GEN, March 12, 2024

Hosted on Acast. See acast.com/privacy for more information.

International Women’s Day, Nanoparticles and Delivery, Novo Nordisk’s Expansion, and Organoids for Congenital Conditions

Fri, 08 Mar 2024 17:39:28 GMT

Episode 12 (March 8, 2024): Featuring Julianna LeMieux (Deputy Editor-in-Chief, GEN), Uduak Thomas (Senior Editor, GEN), and Alex Philippidis (Senior Business Editor, GEN), moderated by Fay Lin (Senior Editor, GEN Biotechnology)

This week, the GEN editors cover a recent interview with the Lost Women of Science, advances in delivery with lipid nanoparticles, Novo Nordisk’s expansion in the Boston area, and how organoids derived from amniotic fluid show promise for understanding fetal diseases.

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

At Lost Women of Science, the Unsung Are Celebrated

By Julianna LeMieux, GEN, March 7, 2024.

To Mark International Women’s Day, C-Suite Women Share Leadership Insights

By GEN, March 7, 2024.

Lipid Nanoparticles Engineered to Target Lung Cells Reduce Tumor Size in Mice

By GEN, March 4, 2024.

Novel Thio-lipids Developed Capable of Reaching Eyes and Lungs in Animals

By GEN, March 5, 2024.

Novo Nordisk Expands Boston Area Research and Early Development

By Alex Philippidis, GEN, March 2, 2024.

Metal-Organic Nanoparticles Enable Better Vaccine Delivery, Stronger Immune Response

By GEN, March 6, 2024.

Organoids Originating from Cells in Amniotic Fluid Could Illiminate Congential Conditions

By GEN, March 5, 2024.

Hosted on Acast. See acast.com/privacy for more information.

Moderna Gets Back to Its Roots, Form Bio and Ginkgo Bioworks Team Up, and Under-the-Radar Rare Autoimmune Diseases

Fri, 01 Mar 2024 16:57:34 GMT

Episode 11 (March 1, 2024): After being diverted by the SARS-CoV-2 pandemic to develop and manufacture COVID-19 vaccines, Moderna gets back to advancing rare disease mRNA therapeutics; a look at rare autoimmune diseases that fly below the public radar; Form Bio announced a partnership with Ginkgo Bioworks to bring their AI out of the computer and into gene therapy production by optimizing genetic payloads.

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

Rare Disease Day: Moderna Gets Back to Its Roots

By Jonathan D. Grinstein, GEN, February 28, 2024

Taming the Immune System When Rare Diseases Strike

By Kathy Liszewski, GEN, February 27, 2024

Form Bio’s AI Ensures Gene Therapies Pass Muster, with Ginkgo’s Help

GEN, February 28, 2024

Hosted on Acast. See acast.com/privacy for more information.

Prime Editing for Isogenic iPSCs, PRINT, Universal In Vivo CAR T Editing, Biogen Q4 Results Disappoint; Andrea Choe

Fri, 23 Feb 2024 17:29:57 GMT

Episode 10 (February 23, 2024): Researchers from Francis Collins’ lab developed an efficient CRISPR prime editing protocol to generate isogenic-induced pluripotent stem cell (iPSC) lines carrying heterozygous or homozygous alleles for putatively causal single nucleotide variants. An RNA-based system known as PRINT can create and introduce site-specific, safe, and stable transgenes into the human genome. Astellas Pharma and Kelonia announced a nearly $800 million research collaboration and license agreement to develop innovative universal, off-the-shelf in vivo CAR T cell therapies. Fourth-quarter earnings and revenue fell short of expectations as Biogen worked to eliminate 1,000 jobs (11.5% of its workforce), among other cost-cutting actions, and restructured its pipeline after a slow start.

Plus, an interview with Andrea Choe, founder and chief executive officer at Holoclara.

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

Generation of Human Isogenic Induced Pluripotent Stem Cell Lines with CRISPR Prime Editing

The CRISPR Journal, February 14, 2024

Addressing Scientific Misconduct: An Interview with Elisabeth Bik

By Uduak Thomas, GEN Biotechnology, February 15, 2024

StockWatch: Biogen’s Q4 Results Disappoint Analysts

By Alex Philippidis, GEN Edge, February 18, 2024

Astellas and Kelonia Partner for $800M In Vivo CAR T Cell Therapies

By Jonathan D. Grinstein, PhD, GEN Edge, February 20, 2024

PRINT: Precise RNA-Mediated Insertion of Transgenes

GEN, February 21, 2024

Hosted on Acast. See acast.com/privacy for more information.

CRISPRed Pigs, Exscientia Fires CEO, & AGBT Roundup; Christian Henry

Fri, 16 Feb 2024 17:36:37 GMT

Episode 9 (February 16, 2024): Using CRISPR-Cas9 technology, British animal genetics firm Genus has generated a population of pigs that are resistant to the deadly porcine reproductive and respiratory syndrome (PRRS) virus. Exscientia has fired its founder, CEO, and principal executive officer Andrew Hopkins, PhD, and removed him from the company’s board, after it concluded that he engaged in “inappropriate” relationships with two employees. Julianna LeMieux, PhD, Deputy Editor in Chief at GEN, provides a recap of her time at AGBT 2024.

Plus, an interview with Christian Henry, president and chief executive officer at PacBio.

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

CRISPRed Pigs: Precision Porcine Gene Editing Combats PPRS Virus Threat

By Uduak Thomas, GEN, February 14, 2024

Exscientia Fires CEO for “Inappropriate” Relationships with Two Employees

GEN, February 13, 2024

Sun, Spatial, and Sequencing: A Report from the First Day of AGBT

By Julianna LeMieux, PhD, and Jonathan D. Grinstein, PhD, GEN, February 7, 2024

NanoString CSO Joe Beechem Insists the Company “Not Going Anywhere”

By Julianna LeMieux, PhD, GEN, February 8, 2024

Hosted on Acast. See acast.com/privacy for more information.

Intellia and Ultragenyx’s Clinical Updates, Novo Holdings’ Catalent Acquisition, and NanoString Bankruptcy; Simon Barnett

Fri, 09 Feb 2024 12:00:53 GMT

Episode 8 (February 9th, 2024): Intellia and Ultragenyx gave updates on their clinical trials for gene therapies for inherited rare diseases. Novo Holdings, which manages the assets of the foundation that controls Novo Nordisk, agreed to buy Catalent for $16.5 billion to keep up with the high demand for its hit drugs Wegovy and Ozempic. Spatial biology tools developer NanoString Technologies filed for bankruptcy, blaming the $31 million jury award assessed against it last November in a patent infringement case filed by rival 10x Genomics. Plus, an interview with Simon Barnett, research director at Dimension.

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

Gene Therapy for Hereditary Angioedema Shows Success in Patients

· GEN, February 5, 2024

Ultragenyx’s Gene Therapy Ameliorates Pediatric Neurodegenerative Disorder

· By Jonathan Grinstein, GEN Edge, February 7, 2024

CRISPR-Repaired T Cells May Treat Fatal Inflammatory Diseases

· GEN, February 5, 2024

NanoString Files for Chapter 11 Bankruptcy, Launches Strategic Review

· By Alex Philippidis, GEN, February 5, 2024

Novo Holdings Buys Catalent for $16.5B; Sells Three Sites to Novo Nordisk for $11B

· By Alex Philippidis, GEN, February 5, 2024

Hosted on Acast. See acast.com/privacy for more information.

Genome Interpretation, Nanoparticles, Gene Therapy, 2024 IPOs; Nautilus Biotechnology

Fri, 02 Feb 2024 18:40:08 GMT

Episode 7 (February 2, 2024): Simplify Genomics launches genome interpretation platform, COUR’s nanoparticles for autoimmunity, gene replacement therapy for heart condition, CG Oncology and ArriVent IPOs; an interview with Nautilus Biotechnology co-founders, Sujal Patel and Parag Mallick.

Listed below are key references to the GEN stories, media and other items discussed in this episode of Touching Base:

Human Longevity Spin-Out Aims to Tap into Variant Interpretation Market

By Uduak Thomas, GEN, January 31st, 2024

Light My Fire: COUR Raises $105M Series A to Advance Tolerogenic Nanoparticles for Autoimmunity

By Jonathan Grinstein, GEN Edge, January 30th, 2024

Gene Replacement Therapy Halts Fatal Arrhythmogenic Condition in Mice

GEN, January 30th, 2024

StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555M

By Alex Philippidis, GEN Edge, January 28th, 2024

Hosted on Acast. See acast.com/privacy for more information.

Restoring Hearing Loss, CAR T Manufacturing, DNA-Based Medicines, Nvidia and Recursion; Eric Topol

Fri, 26 Jan 2024 20:36:29 GMT

Episode 6 (January 26, 2024): 11-year-old regains hearing after gene therapy; Kyverna uses blood draw instead of apheresis for CAR T manufacturing; DNA production technology with GSK and Elegen, StockWatch with Nvidia and Recursion; an interview with renowned cardiologist, Eric Topol, MD

Listed below are key references to the GEN stories, media and other items discussed in this episode of Touching Base:

Gene Therapy Restores Hearing in 11-Year-Old After Just One Month

GEN, January 24th, 2024

GSK and Elegen Team Up to Develop DNA-Based Medicines and Vaccines

By Jonathan Grinstein, GEN Edge, January 24th, 2024

Blood Brothers: Kyverna Reinvents Autologous CAR T Manufacturing from Blood Draw

By Jonathan Grinstein, GEN Edge, January 24th, 2024

StockWatch: Nvidia Jumps 24% on Recursion, Amgen AI Partnerships

By Alex Philippidis, GEN Edge, January 21st, 2024

Five Deaf Children Have Hearing Restored by AAV-Based Gene Therapy

GEN, January 25th, 2024

Hosted on Acast. See acast.com/privacy for more information.

Alzheimer’s Disease, Monkey Cloning, Cytokinetics Stock; Jen Nwankwo

Thu, 18 Jan 2024 21:39:11 GMT

Episode 5 (January 19, 2024); RNAs to address Alzheimer’s disease; monkey cloned via somatic cell nuclear transfer; Cytokinetics stock roller coaster; an interview with founder and CEO of 1910 Genetics, Jen Nwankwo, PhD.

Listed below are key references to the GEN stories, media and other items discussed in this episode of Touching Base:

· Alzheimer’s Disease Linked to Toxic Short RNAs

GEN, January 18, 2024.

· Rhesus Monkey Cloned via Somatic Cell Nuclear Transfer

GEN, January 16, 2024.

· StockWatch: M&A Talk Fuels Cytokinetics Stock Roller Coaster

By Alex Philippidis, GEN Edge, January 16th, 2024.

Hosted on Acast. See acast.com/privacy for more information.

J.P. Morgan 2024: Illumina, 10x, Danaher, AI; Liberate Bio

Thu, 11 Jan 2024 18:59:43 GMT

Episode 4 (January 12, 2024): Takeaways from the J.P. Morgan Health Care conference: Illumina, Danaher, 10x, Empress Therapeutics; an interview with Liberate Bio’s Shawn Davis and Walter Strapps.

Listed below are references to relevant GEN stories discussed in this episode of Touching Base:

JPM: Illumina’s new CEO spells out 2024 priorities, presents preliminary Q4 2023 results

By Alex Philippidis, GEN, January 10, 2024.

JPM: Prime Medicine eyes 2024 IND for first prime editing therapy

By Alex Philippidis, GEN, January 9, 2024

JPM 2024: Veracyte’s C2i genomics acquisition adds AI readouts to liquid biopsy testing

By Jonathan D. Grinstein, GEN, January 8, 2024

JPM: More M&A “firepower” in store for 2024, EY predicts

By Alex Philippidis, GEN, January 8, 2024

Hosted on Acast. See acast.com/privacy for more information.

Novartis and Voyager, JPM Ahead, Epigenetic Engineering; Alex Aravanis

Fri, 05 Jan 2024 16:28:14 GMT

Episode 3 (January 5, 2024): Interview with Co-founder and CEO of Moonwalk Biosciences and former CTO of Illumina, Alex Aravanis; Neuro gene therapy with Novartis and Voyager; GEN reporters look forward to the 2024 J.P. Morgan Healthcare Conference

Listed below are key references to the GEN stories, media and other items discussed in this episode of Touching Base:

Novartis, Voyager Ink Up-to-$1.3B Expansion of Neuro Gene Therapy Collaboration

By Alex Philippidis, GEN, January 2, 2024.

Moonwalk Biosciences Raises $57M to Edit the Epigenome

By Uduak Thomas, GEN, January 4, 2024.

Hosted on Acast. See acast.com/privacy for more information.

Launch of Tome Biosciences, AI scientist, mRNA vaccines

Thu, 21 Dec 2023 18:33:43 GMT

Episode 2 (December 22, 2023): Interview with President and CEO of Tome Biosciences, Rahul Kakkar; intelligent lab partner using LLMs; AI for antimicrobials; mRNA vaccine production in Africa; Moderna’s positive cancer vaccine data.

Listed below are key references to the GEN stories, media and other items discussed in this episode of Touching Base:

The Next Chapter in Genome Editing? Tome Emerges from Stealth with $213M By Alex Philippidis, GEN, December 19, 2023.
Artificial Intelligence-Based Lab Partner Designs, Runs Experiments in the Lab GEN, December 20, 2023.
BioNTech Advances Plans for mRNA Vaccine Production in Africa by 2025 GEN, December 19, 2023.
Explainable AI Directs Small Molecule Structural Class Drug Discovery By Jonathan Grinstein, GEN, December 20, 2023.
StockWatch: Positive Cancer Vaccine Data Wows Moderna Investors By Alex Philippidis, GEN Edge, December 18, 2023.

Hosted on Acast. See acast.com/privacy for more information.

Autism, AI and Epigenetics; Nevan Krogan

Fri, 08 Dec 2023 19:29:47 GMT

Episode 1 (Week ending December 8, 2023): Nevan Krogan (UCSF) mapping autism pathways; Nvidia’s latest AI partnership; CAR-T regulations; epigenome editing; mRNA therapeutics.

References to the GEN stories, media and other items discussed in this episode of Touching Base:

· Autism’s Molecular Mechanisms Uncovered through Protein-Protein Interaction Network

By Julianna Lemieux, GEN, December 5, 2023.

· Rhapsody in B: Tune Therapeutics Presents Data for Hepatitis B Epigenetic Silencer

By Jonathan Grinstein, GEN Edge, December 6, 2023.

· Nvidia Looks to Genentech for its Next Leap in AI Drug Discovery

By Alex Philippidis, GEN Edge, November 28, 2023.

· StockWatch: CAR-T Shares Mostly Flat as FDA Probes Risk of New Cancers

By Alex Philippidis, GEN, December 1, 2023

· Perfect Pitch: Genome Editing Pioneer Fyodor Urnov on Commercializing CRISPR Therapies and Epigenomic Tuning {VIDEO}

GEN Edge, August 30, 2023

· Press release: John Crowley appointed President & CEO of BIO

Biotechnology Innovation Organization

· BIO CEO Rachel King Outlines Industry’s Challenges on “Close to the Edge”

GEN multimedia, April 26, 2023

· The First CRISPR Drug: Vertex Pharmaceuticals’ Casgevy Wins U.K. Approval for Sickle Cell Disease

GEN, November 16, 2023

Hosted on Acast. See acast.com/privacy for more information.